Navigation Links
Epizyme, Inc. to Be Added to NASDAQ Biotechnology Index (NBI) and NASDAQ Global Select Market
Date:12/20/2013

CAMBRIDGE, Mass., Dec. 20, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective before market open on December 23, 2013.  Epizyme also announced that its common stock will be transferred to the NASDAQ Global Select Market effective January 2, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund (Nasdaq: IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index.  In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

The NASDAQ Global Select Market is the top listing tier for NASDAQ companies, with the highest initial listing standards in the world.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Epizyme, Inc. Provides Third Quarter 2013 Financial Results and Corporate Update
2. Epizyme, Inc. Reports Second Quarter 2013 Financial Results
3. Global Bulk Molding Compounds Market and China LOW-E Glass Analysis in New Research Added to DeepResearchReports.com
4. Welcome guests: Added molecules allow metal-organic frameworks to conduct electricity
5. MarketPublishers.com Added New Report on Thujone, (A + B)(SG) (CAS 2867-05-2) Market to Its Catalogue
6. MarketPublishers.com Added New Report on Silicon Nitride (CAS 12033-89-5) Market to Its Catalogue
7. MarketPublishers.com Added New Report on Chlorinated Polypropylene (CAS 68442-33-1) Market to Its Catalogue
8. MarketPublishers.com Added New Report on Sodium Nitrite (CAS 7632-00-0) Market to Its Catalogue
9. MarketPublishers.com Added New Report on Levocarnitine (CAS 541-15-1) Market to Its Catalogue
10. MarketPublishers.com Added New Report on Hydroxyethyl Starch (CAS 9005-27-0) Market to Its Catalogue
11. MarketPublishers.com Added New Report on Povidone Iodine (CAS 25655-41-8) Market to Its Catalogue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... and biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control ... vendor-supported, portable online UHPLC, with robust, probe-based sampling. , Online liquid ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... Nov. 30, 2016  GenomOncology today announced the appointment of ... Medical Affairs.  Dr. Coleman will oversee clinical ... proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists ... data and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... , Nov. 30, 2016 Biotest Pharmaceuticals ... is pleased to announce the addition of its newest ... Kearney, Nebraska . The 15,200 square foot ... November 29th, 2016 and brings the total number of ... Ileana Carlisle , BPC,s Chief Executive Officer said ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
Breaking Biology News(10 mins):